Pfizer is a research-based biopharmaceutical global company, developing and manufacturing human and veterinary medicines, as well as consumer healthcare products. The Company applies science and its global resources to improve health and well-being at every stage of life. Pfizer's diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many consumer health care products. The Company operates in two business segments: biopharmaceutical and diversified. Biopharmaceutical includes the primary care, specialty care, established products, emerging markets and oncology customer-focused units. Diversified includes animal health products that prevent and treat diseases in livestock and companion animals, and consumer healthcare products. Pfizer develops and produces medicines and vaccines for a wide range of conditions including in the areas of immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain. The Company's products include Lipitor (atorvastatin, used to lower LDL blood cholesterol), Lyrica (pregabalin, for neuropathic pain/fibromyalgia), Diflucan (fluconazole, an oral antifungal medication), Zithromax (azithromycin, an antibiotic), Viagra (sildenafil, for erectile dysfunction) and Celebrex/Celebra (celecoxib, an anti-inflammatory drug).

Company Growth (employees)
New York, US
Size (employees)
96,500 (est)
Pfizer was founded in 1848 and is headquartered in New York, US

Key People at Pfizer

Ian C. Read

Ian C. Read

Chairman & CEO
Frank A. D'Amelio

Frank A. D'Amelio

EVP, CFO & Business Operations
Laurie J. Olson

Laurie J. Olson

EVP of Strategy, Portfolio and Commercial Operations
Chuck Hill

Chuck Hill

Executive Vice President, Worldwide Human Resources
Rady Johnson

Rady Johnson

Executive VP, Chief Compliance And Risk Officer
Mikael Dolsten

Mikael Dolsten

President, Worldwide Research & Development
Doug Lankler

Doug Lankler

Executive VP, General Counsel
Freda C. Lewis-Hall

Freda C. Lewis-Hall

EVP & Chief Medical Officer

Pfizer Office Locations

Pfizer has offices in New York, Buenos Aires, Bentley, Shanghai and in 37 other locations
New York, US (HQ)
235 East 42nd Street
Show all (42)

Pfizer Data and Metrics

Pfizer Financial Metrics

Pfizer's revenue was reported to be $52.8 b in FY, 2016 which is a 8% increase from the previous period.

Revenue (FY, 2016)

52.8 b

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

40.5 b

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

7.2 b

EBIT (FY, 2016)

7.2 b

Market capitalization (22-Sep-2017)

217.1 b
Pfizer's current market capitalization is $217.1 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


51.6 b49.6 b48.9 b52.8 b

Revenue growth, %


Cost of goods sold

9.6 b9.6 b9.6 b12.3 b

Gross profit

42 b40 b39.2 b40.5 b
USDY, 2011Y, 2012FY, 2013FY, 2014FY, 2015FY, 2016


3.2 b10.1 b2.2 b3.3 b3.6 b


6.2 b5.7 b

Current Assets

56.2 b57.7 b43.8 b38.9 b


12.4 b11.8 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

22.1 b9.2 b

Accounts Receivable

940 m148 m21 m(134 m)


(538 m)175 m(199 m)365 m

Accounts Payable

382 m297 m254 m871 m
USDY, 2016


543.5 k
Show all financial metrics

Pfizer Operating Metrics

Y, 2014Y, 2015Y, 2016

Active Clinical Studies


Phase III Trials


Discovery Projects


Drugs Approved by FDA

Show all operating metrics

Pfizer Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
MedivationAugust 22, 2016$14 b
Anacor PharmaceuticalsJune 24, 2016$5.2 b
AllerganNovember 23, 2015$160 b

Pfizer Market Value History

Pfizer Revenue Breakdown

Pfizer Median Salaries

Source: 241 public H-1B filings from Pfizer

Traffic Overview of Pfizer

Pfizer Online and Social Media Presence

Pfizer News and Updates

Global Gout Disease Treatment Market Intelligence, Share Analysis and Product Research 2015

The increase in the number of gout disease incidences and strong development of the treatment are some of the major factors driving the global gout disease treatment market. Posted via Industry Today. Follow us on Twitter @IndustryToday

FiercePharmaAsia—Big Pharma’s performance, Fosun’s revised Gland buy, Arcus-Taiho cancer deal

Pfizer leads Big Pharma's emerging markets growth as GlaxoSmithKline and Eli Lilly lag behind, Fosun is buying a smaller 74% stake in Gland Pharma, Japan's Taiho has inked a $35 million option deal to gain access to Arcus' cancer immunotherapy portfolio and more.

Tardive Dyskinesia (TD) Treatment Market Analysis by Size & Share by 2024

The market for the tardive dyskinesia treatment will grow significantly in the coming years. The key factor that is driving the tardive dyskinesia treatment market is the increasing number of people that are suffering from the neurological disorders. Posted via Industry Today. Follow us on Twitter @…

Pfizer's fast-growing Ibrance romps toward an early $5B payoff: analyst

The breast cancer medication Ibrance has been the shooting star in Pfizer’s universe, and it’s expected to burn brightly enough to raise the entire company’s fortunes. Almost $5 billion bright in 2018, if one analyst's predictions come true.

Pfizer hits a snag in bid to jump-start Sutent's flagging kidney cancer sales

Pfizer is counting on a new approval for Sutent, its kidney cancer drug, but an FDA advisory panel isn’t so sure—and a disappointing committee vote this week followed another threat in the form of positive kidney cancer data for Bristol-Myers’ Opdivo-Yervoy combo.

A law professor’s big idea for combatting greedy drug company titans like Martin Shkreli

In 2015, CEO of Turing Pharmaceuticals Martin Shkreli infamously raised the price of the life-saving drug Daraprim by 5,000%. Daraprim, developed more than 60 years…
Show more

Pfizer Company Life and Culture

You may also be interested in